What does Revogan do?
Revogan is a biotechnology company that specializes in developing innovative solutions for regenerative medicine. Their focus is on harnessing the power of stem cells and advanced biomaterials to promote tissue healing and regeneration. By combining research and technological advancements, Revogan aims to improve patient outcomes in various medical applications.
- Sectors
- Wholesalers
- Signals
-
ProfitableProfitable € 62K
The company reported a positive net result in the latest financial year.
Strong equityStrong equity € 2.89MStrong equity provides a buffer against setbacks.
Low riskLow risk 42.1%Good solvency (> 30%) points to long-term financial stability.
Good liquidityGood liquidity 1.63A healthy current ratio (≥ 1.5): enough current assets to cover short-term debt.
Positive cashflowPositive cashflow € 387KPositive operating cash flow in the latest financial year.
Positive EBITDAPositive EBITDA € 894KPositive EBITDA: operating activities are profitable.
High turnoverHigh turnover € 17.76MSubstantial turnover in the latest financial year.
Healthy social debtHealthy social debt 13.5%Social debts stay manageable relative to personnel costs.
- Shareholders
- Kinjema 92,29%
- Investments
- Biscardy's 100%
Financial ratios
|
max) max = w;
}
}
const wClamped = Math.max(120, Math.min(800, max));
colWidths[''] = wClamped;
save && save();
})(event)">
|
2025
max) max = w;
}
}
const wClamped = Math.max(120, Math.min(800, max));
colWidths[''] = wClamped;
save && save();
})(event)">
|
2024
max) max = w;
}
}
const wClamped = Math.max(120, Math.min(800, max));
colWidths[''] = wClamped;
save && save();
})(event)">
|
2023
max) max = w;
}
}
const wClamped = Math.max(120, Math.min(800, max));
colWidths[''] = wClamped;
save && save();
})(event)">
|
2022
max) max = w;
}
}
const wClamped = Math.max(120, Math.min(800, max));
colWidths[''] = wClamped;
save && save();
})(event)">
|
|---|---|---|---|---|
|
€
17.76M
|
€
17.56M
|
€
17.31M
|
€
15.92M
|
|
|
€
894K
|
€
579K
|
€
518K
|
€
588K
|
|
|
€
62K
|
€
199K
|
€
192K
|
€
248K
|
|
|
€
2.89M
|
€
2.82M
|
€
2.63M
|
€
2.43M
|
|
|
42.05%
|
35.33%
|
32.36%
|
32.31%
|
|
|
€
3.98M
|
€
5.17M
|
€
5.49M
|
€
5.10M
|
|
|
€
257K
|
€
231K
|
€
485K
|
€
474K
|
|
|
20.60
|
20.80
|
22.60
|
22.90
|
Publications 62
All publications- Ontslagen - Benoemingen 17/07/2024
- Ontslagen - Benoemingen 06/06/2024
- Statuten (Vertaling, Cordinatie, Overige Wijzigingen, ) - Ontslagen - Benoemingen 24/04/2024
- Ontslagen - Benoemingen 19/10/2021
- Ontslagen - Benoemingen 17/03/2021
Frequently asked questions
Answers to the most common questions about Revogan, based on official government data and the filed annual accounts.
What is the VAT number of Revogan?
The VAT number of Revogan is BE0401.084.409.
How many employees work at Revogan?
In 2025, Revogan employed 20.60 full-time equivalents (FTE).
When was Revogan established?
Revogan was founded in 10-07-1965.
What is the official address of Revogan?
The official address of Revogan is Landegemstraat 1 Gent 9031.
What is the legal form of Revogan?
The juridical form of Revogan is Public limited company (NV/SA).
What is the annual revenue of Revogan?
The revenue of Revogan for the 2025 financial year was €17,758,363.
What does Revogan do?
Revogan is a biotechnology company that specializes in developing innovative solutions for regenerative medicine. Their focus is on harnessing the power of stem cells and advanced biomaterials to promote tissue healing and regeneration. By combining research and technological advancements, Revogan aims to improve patient outcomes in various medical applications.
Is Revogan a reliable company?
Revogan is a registered Rechtspersoon with company number 0401.084.409 and can be verified through the official CBE database.
What is the credit limit of Revogan?
The estimated credit limit of Revogan is €1,802,982.
Is Revogan still active?
Revogan currently has the status "Normal situation" and is active.